Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 15, 2019. The document serves as a transaction notification regarding a specific securities transaction involving a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is a regulatory disclosure of a single transaction rather than a financial results report.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of American Depositary Shares (ADSs) |
| Instrument ISIN | US37733W1053 |
| Transaction Price | $39.4400 per ADS |
| Transaction Volume | 27,374 ADSs |
| Transaction Date | January 11, 2019 |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details an acquisition of ADSs by Mr. B McNamara (CEO, GSK Consumer Healthcare) following the re-investment of dividends paid on January 10, 2019, under the Deferred Annual Bonus Plan Post-Tax.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is strictly a notification of a PDMR transaction.
Key Facts for Investor Verification
- The transaction was an acquisition of 27,374 ADSs at $39.44 per share.
- The purchase was executed on January 11, 2019, on the NYSE.
- The transaction was driven by the automatic re-investment of dividends for the Deferred Annual Bonus Plan Post-Tax.
- The filing does not contain any new financial performance data for GSK Plc.